Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents
Recommended Citation
Klamer KS, Bhargava A, Johnson L, Sharma M, Saravolatz LD. Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents. JAC Antimicrob Resist. 2026;8(3):dlag089.
Document Type
Article
Publication Date
6-1-2026
Publication Title
JAC Antimicrob Resist
Abstract
BACKGROUND: Candidozyma auris (C. auris) is a resistant fungal pathogen with high mortality. OBJECTIVES: To evaluate the in vitro activity of 11 antifungal agents against C. auris from multiple hospitals. METHODS: MIC was determined by microdilution testing for amphotericin B, anidulafungin, caspofungin, manogepix, micafungin, rezafungin and five triazoles. Sanger sequencing was performed on one echinocandin resistant isolate. RESULTS: There were 84 C. auris isolates from Michigan that were compared with 27 organisms from external sources. Manogepix had the lowest MIC(90) (0.03 mg/L). The next most active agent was micafungin. The echinocandins demonstrated a 98.8% susceptibility. A single isolate was found to have a S639F mutation. Amphotericin B demonstrated a 97.6% susceptibility. The MIC(90) demonstrated values of ≤0.5 mg/L for isavuconazole, itraconazole and posaconazole. When separating by colonization versus infection isolates, the MIC(90) values were identical for all agents, except micafungin, which showed 0.25 versus 0.12 mg/L, respectively. When comparing the reference isolates with Michigan isolates, the MIC(90) was identical for echinocandins and manogepix. Differences noted were with amphotericin B, for which 85.2% were susceptible for reference isolates compared to 97.6% from Michigan isolates, and fluconazole, where 25.9% were susceptible for the reference isolates compared with 4.8% from Michigan isolates. CONCLUSIONS: Manogepix and echinocandins demonstrated the greatest activity against C. auris irrespective of hospital and were like the reference isolates. Amphotericin B demonstrated greater activity compared with published studies. Fluconazole has poor activity; the activity of other triazoles remains unclear.
PubMed ID
42211724
Volume
8
Issue
3
First Page
089
Last Page
089
